Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Flynn

Showing results (331-340 of 342) with videos related to

Pageof 35
Sort By:
Pathogens & Immunity|May 20, 2026
Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19Evelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Cell Reports. Medicine|July 6, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish C Choudhary, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 7, 2021
Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After VaccinationCrystal M North, Amy Barczak, Robert H Goldstein, et al.
AIDS and Behavior|August 11, 2019
Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the GlobeL Stranix-Chibanda, S Brummel, J Pilotto, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody ResponsesMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
JCI Insight|October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variantMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2021
SARS-CoV-2 Viremia is Associated with Distinct Proteomic Pathways and Predicts COVID-19 OutcomesYijia Li, Alexis M Schneider, Arnav Mehta, et al.
The Journal of Clinical Investigation|July 1, 2021
SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomesYijia Li, Alexis M Schneider, Arnav Mehta, et al.
Pageof 35

Showing results (331-340 of 342) with videos related to

Sort By:
Pageof 35
Pathogens & Immunity|May 20, 2026
Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19Evelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Cell Reports. Medicine|July 6, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish C Choudhary, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 7, 2021
Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After VaccinationCrystal M North, Amy Barczak, Robert H Goldstein, et al.
AIDS and Behavior|August 11, 2019
Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the GlobeL Stranix-Chibanda, S Brummel, J Pilotto, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody ResponsesMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
JCI Insight|October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variantMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2021
SARS-CoV-2 Viremia is Associated with Distinct Proteomic Pathways and Predicts COVID-19 OutcomesYijia Li, Alexis M Schneider, Arnav Mehta, et al.
The Journal of Clinical Investigation|July 1, 2021
SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomesYijia Li, Alexis M Schneider, Arnav Mehta, et al.
Pageof 35